WCG IRB + AstraZeneca (IRB)
For twenty years, AstraZeneca and WCG IRB have stood together as partners advancing research within the pharmaceutical industry. As a valued client, we are excited to share resources with you that we trust will be helpful as we continue our partnership.
Within this microsite – custom built for AstraZeneca – we are proud to connect you to your dedicated team, highlight an important initiative that streamlines your start-up programs, and provides a slew of resources to get your jobs done efficiently, effectively, and easily.
To immediately get started on new projects, all we need are a few details about your study via email (protocol number, number of expected US/Canadian sites in the study, and anticipated start date).
Empowering Research and Advancing Health, Together
Thank you for your continued trust in WCG IRB Solutions.
Once we connect on your study, we will provide the following complimentary services:
- Site list review (how each site works with WCG)
- Virtual training in the WCG IRB Connexus portal
- Pre-review of your submission form and addressing your ethical/regulatory questions
- Kick-off call for every new study with your designated Client Partnership Director
Studies Completed
Average TAT
(Full Board / Expedited)
Number of PIs
(Sites)
AstraZeneca’s Account Team
Brian Slack
Senior Director of Business Development, WCG IRB
330.697.4642
bslack@wcgclinical.com
Joel Parke, CIP
Client Partnership Director,
WCG IRB
919.287.6609
jparke@cgirb.com
Supporting Your Sites and Institutions
Sites you work with may be new to the WCG IRB ConnexusTM portal, and they may ask you for help. To ensure your sites are comfortable with the system, we have published an Orientation Guide that you can download and send directly to them.
Introducing IRB+
Do you have a study that needs an extra level of premium attention and white glove service to ensure accelerated timelines without sacrificing the quality of the ethical review? IRB+ provides a fully-dedicated team, working 7-days per week, providing personalized oversight of your entire study throughout the entire operational process.
WCG’s Processing and Review Turnaround Times (TAT) Target vs. Actual*
| Type of review | target tat | actual* tat |
|---|---|---|
| New Protocol (Full Board) | 8.0 | 5.9 |
| New Protocol (Expedited) | 3.7 | 2.2 |
| New Investigator (Standard) | 2.0 | 2.2 |
| New Investigator (Customized) | 5.0 | 3.7 |
| Translation | 3.7 | 3.0 |
| Change in Research (Expedited – No Consent Forms) | 3.7 | 2.1 |
| Change in Research (Expedited – With Consent Forms) | 3.7 | 2.8 |
| Change in Research (Full Board – No Consent Forms) | 8.0 | 6.1 |
| Change in Research (Full Board – With Consent Forms) | 8.0 | 6.6 |
Helpful Resources
Understand why WCG is the Industry’s Gold Standard IRB, and what makes us different than all others:
Explore the lists of 3,400+ Institutions and 600+ IBC sites in the WCG network:
Gain insights from our IRB and IBC experts in our “Ask the Experts” Forum:
Learn what you need to know about ethical and biosafety oversight of gene transfer in clinical research:
Do you need to update contact information for protocol-level communications (e.g. holds)?
See how a Top-5 Pharma company was able to enroll 4,600 patients for a study:
Billing & Invoicing Information
Access the IRB Billing Information Form, which you can provide to us for all sites who rely on the same billing instructions.
Questions for our Accounts Receivable team?
Email: ar@wcgclinical.com.
Frequently Used Forms
Is there additional information you would like to have us post here for quick access? Please let us know!
Meet the Executive Team Dedicated to AstraZeneca
Tim Schuckman
Chief Commercial Officer
